XBIOTECH INC (XBIT)

Company Profile

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2015-04-15. The firm is engaged in advancing a pipeline of therapies by harnessing naturally occurring antibodies from patients with immunity to certain diseases. The firm develops True Human monoclonal antibodies for treating a variety of diseases. True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The firm is focused on therapies that block a potent substance known as interleukin-1 alpha (IL-1a), which mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma, In almost all chronic and some acute injury scenarios (such as stroke or heart attack).

Company Info

XBIOTECH INC

5217 Winnebago Lane

Austin TEXAS 78744

P: 15123862900

CEO: John Simard

Employees: 85

Website: http://www.xbiotech.com/